CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Outset Medical Q3 revenue rises as net loss narrows

By Reuters News


Overview

  • U.S. dialysis technology firm's Q3 revenue rose 14% yr/yr to $33.6 mln

  • Gross margin for Q3 expanded to 40.7% from 39.4% yr/yr

  • Net loss for Q3 narrowed to $14.7 mln from $17.8 mln a year earlier


Outlook

  • Outset reiterates 2026 revenue guidance of $125 mln to $130 mln

  • Company expects 2026 non-GAAP gross margin in low-40% to mid-40% range

  • Company reiterates 2026 revenue and non-GAAP gross margin guidance


Result Drivers

  • CONSOLE SALES - Co said higher console revenue contributed to overall revenue growth

  • RECURRING REVENUE - Growth in sales of Tablo consumables and services supported quarterly revenue

  • GROSS MARGIN EXPANSION - Higher service and other gross margin helped lift overall gross margin to 40.7% from 39.4%


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

$14.69 mln

Q3 Gross Margin

40.70%

Q3 Gross Profit

$13.67 mln

Q3 Loss Per Share

$0.78

Q3 Operating Expenses

$25.94 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Outset Medical, Inc. is $7.00, about 68.7% above its November 3 closing price of $4.15


Reuters Recommended Reads

  • Nov 3 - Germany's Fresenius Medical says Q3 results weighed by China; narrows forecast

  • Nov 4 - Healthcare firm Fresenius Q3 revenue rises on Kabi growth; lifts outlook

  • Nov 2 - Denmark medical devices maker Coloplast's Q4 revenue rises


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.